Thursday, May 13, 2021 Daily Archives

Ensuring Viral Safety in Cell & Gene Therapy Through Next-Generation Sequencing

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Horst Ruppach, Senior Scientific and Portfolio Director, Global Biologics, Charles River The viral contamination risk of cell and gene therapy products is significant. Multiple factors open the windows for viruses to enter the process. The current viral risk mitigation strategies have limitations and can either not be applied or have limitations to cover a broader range of potential viral contaminants. One of the most important entry points to monitor are the cells. They are used to produce…

Athenex adds allogeneic assets in $70m Kuur Therapeutics deal

Athenex will leverage its manufacturing capabilities and staff to support the development of Kuur’s NKT cell therapies. Biopharma firm dedicated to developing cancer treatments Athenex has acquired Kuur Therapeutics, a developer of engineered Natural Killer T (NKT) cell therapies used to treat haematological and solid malignancies. Through the acquisition Kurr could receive up to $185 million, through a $70 million upfront payment from Athenex and $115 million in development milestones. According to Athenex, it is not just financial benefit that…